Intranasal data

Aviron announced that its vaccine showed efficacy in a trial of 92 adult volunteers with influenza. A preliminary analysis of the data had been unclear as to efficacy, but complete analysis has shown statistically significant results.

Laboratory-documented flu illness occurred in seven percent of the volunteers given Aviron's vaccine, compared to 13 percent injected with a standard trivalent inactivated influenza vaccine, and 45 percent of those given placebo. Vaccination with the intranasal agent gave 85 percent protection, and the inactivated vaccine gave 71 percent protection. All comparisons were statistically significant. The data were presented at the IBC Influenza and Other Respiratory Disorders meeting in Washington. ...